UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

British journal of dermatology (1951), 2013-07, Vol.169 (1), p.137-145

2013

Volltextzugriff (PDF)

GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID‐19 infection

Journal of gastroenterology and hepatology, 2022-07, Vol.37 (7), p.1400-1401

2022

Volltextzugriff (PDF)

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Annals of oncology, 2020-06, Vol.31 (6), p.780-788

2020

Volltextzugriff (PDF)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib

Clinical pharmacology and therapeutics, 2017-06, Vol.101 (6), p.745-753

2017

Volltextzugriff (PDF)

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

American journal of transplantation, 2015-06, Vol.15 (6), p.1644-1653

2015

Volltextzugriff (PDF)

Editorial: does disease extension lead to disease progression in proctitis?

Alimentary pharmacology & therapeutics, 2017-07, Vol.46 (2), p.205-206

2017

Volltextzugriff (PDF)

Editorial: inflammatory bowel disease risk reduction after migration – are early life events important?

Alimentary pharmacology & therapeutics, 2017-05, Vol.45 (10), p.1367-1368

2017

Volltextzugriff (PDF)

Assessment of Baseline Active Bone Marrow Volume and Correlation to Baseline Hematologic Parameters for Pelvic Malignancies

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E633-E633

2016

Volltextzugriff (PDF)

Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i4

2019

Volltextzugriff (PDF)

The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation

Clinical & translational oncology, 2018-06, Vol.20 (6), p.713-718

2018

Volltextzugriff (PDF)

Evaluation of non-invasive marker of esophageal varices in cirrhosis of liver

Journal of family medicine and primary care, 2020-02, Vol.9 (2), p.992-996

2020

Volltextzugriff (PDF)

Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Annals of oncology, 2018-10, Vol.29, p.viii649-viii650

2018

Volltextzugriff (PDF)

A Comparison of Dosimetric Parameters in PET-Based Active Bone Marrow Volume and Total Bone Volume in Prediction of Hematologic Toxicity in Cervical Cancer Patients Treated with Chemoradiation

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E307-E308

2016

Volltextzugriff (PDF)

THU0192 Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.255-255

2016

Volltextzugriff (PDF)

Salivary Gland Lymphoproliferative Disorders: A Canadian Tertiary Center Experience

Head & neck pathology (Totowa, N.J.), 2013-12, Vol.7 (4), p.381-388

2013

Volltextzugriff (PDF)

THU0188 Evaluation of Single-dose and Steady-State Pharmacokinetics, Bioavailability and Tolerability of the Modified Release Formulation of Tofacitinib vs the Immediate Release Formulation of Tofacitinib in Healthy Volunteers

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.262-263

2015

Volltextzugriff (PDF)

SU‐E‐T‐03: A Comparison of HDR Near Source Dosimetry Using a Treatment Planning System, Monte Carlo Simulation, and Radiochromic Film

Medical Physics, 2013-06, Vol.40 (6), p.203-203

2013

Volltextzugriff (PDF)

SU‐E‐T‐180: Empirical Determination of Output Factors for Proton Therapy Fields Using a Uniform Scanning Proton Beam and 10cm Snout

Medical Physics, 2013-06, Vol.40 (6), p.245-245

2013

Volltextzugriff (PDF)

Evaluation of Respiratory Gating of ROI Definition on the Accuracy of SUV in F18 -FDG PET Imaging

International journal of radiation oncology, biology, physics, 2010-11, Vol.78 (3), p.S814-S814

2010

Volltextzugriff (PDF)

THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.258-259

2015

Volltextzugriff (PDF)

Severe rhabdomyolysis and celiac disease

Digestive and liver disease, 2015-10, Vol.47, p.e272-e272

2015

Volltextzugriff (PDF)

THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.258-258

2016

Volltextzugriff (PDF)

SU‐E‐J‐192: A Method For Estimating Delivered Dose To Head‐And‐Neck Cancer Patients Treated With IMRT

Medical Physics, 2013-06, Vol.40 (6), p.195-195

2013

Volltextzugriff (PDF)

Drug rash with eosinophilia and systemic syndrome (DRESS)/hemofagocytic lymphohistocytosis (HLH) overlap in a child with acute liver failure presentation

Digestive and liver disease, 2016-10, Vol.48, p.e255-e255

2016

Volltextzugriff (PDF)

THU0143 Pharmacokinetics, Bioavailability and Safety of A Modified Release Once Daily Formulation of Tofacitinib in Healthy Volunteers

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.228-228

2014

Volltextzugriff (PDF)

1 – 25 von 907

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(788)
Mit Volltextzugriff
(736)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(378)
MEDLINE
(340)
EZB Electronic Journals Library
(337)
Ovid Journals
(294)
Access via ScienceDirect (Elsevier)
(237)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(157)
Wiley-Blackwell Journals
(150)
Publisher or Other Site
(145)
IngentaConnect Journals
(98)
Wiley Online Library
(80)
Springer journals
(61)
IEEE Xplore Digital Library
(41)
Taylor & Francis Journals
(38)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(35)
Taylor & Francis
(33)
Taylor & Francis Online
(32)
Oxford journals
(28)
Nature Journals
(25)
SAGE Journals Online
(21)
Nexis Uni
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID‐19 infection

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

Editorial: does disease extension lead to disease progression in proctitis?

Editorial: inflammatory bowel disease risk reduction after migration – are early life events important?

Assessment of Baseline Active Bone Marrow Volume and Correlation to Baseline Hematologic Parameters for Pelvic Malignancies

Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation

Evaluation of non-invasive marker of esophageal varices in cirrhosis of liver

Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

A Comparison of Dosimetric Parameters in PET-Based Active Bone Marrow Volume and Total Bone Volume in Prediction of Hematologic Toxicity in Cervical Cancer Patients Treated with Chemoradiation

THU0192 Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis

Salivary Gland Lymphoproliferative Disorders: A Canadian Tertiary Center Experience

THU0188 Evaluation of Single-dose and Steady-State Pharmacokinetics, Bioavailability and Tolerability of the Modified Release Formulation of Tofacitinib vs the Immediate Release Formulation of Tofacitinib in Healthy Volunteers

SU‐E‐T‐03: A Comparison of HDR Near Source Dosimetry Using a Treatment Planning System, Monte Carlo Simulation, and Radiochromic Film

SU‐E‐T‐180: Empirical Determination of Output Factors for Proton Therapy Fields Using a Uniform Scanning Proton Beam and 10cm Snout

Evaluation of Respiratory Gating of ROI Definition on the Accuracy of SUV in F18 -FDG PET Imaging

THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib

Severe rhabdomyolysis and celiac disease

THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

SU‐E‐J‐192: A Method For Estimating Delivered Dose To Head‐And‐Neck Cancer Patients Treated With IMRT

Drug rash with eosinophilia and systemic syndrome (DRESS)/hemofagocytic lymphohistocytosis (HLH) overlap in a child with acute liver failure presentation

THU0143 Pharmacokinetics, Bioavailability and Safety of A Modified Release Once Daily Formulation of Tofacitinib in Healthy Volunteers

Suchergebnisse filtern